---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-008300"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:26:31.584694+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q3 FY2026: Revenue $9.02B (+6% organic), non-GAAP EPS $1.36 beats guidance; reiterates FY outlook

## Summary
- GAAP diluted EPS $0.89; non-GAAP diluted EPS $1.36, three cents above Q3 guidance mid-point.
- Cardiovascular portfolio revenue $3.46B (+10.6% organic); Cardiac Ablation Solutions up 80% on pulsed field ablation.
- Diabetes revenue $796M (+8.3% organic); Neuroscience $2.56B (+2.5% organic); Medical Surgical $2.17B (+2.7% organic).
- Reiterates FY26 organic revenue growth ~5.5% and non-GAAP EPS guidance $5.62-$5.66, including ~$185M tariff impact.
- Secured FDA clearances for Hugo robotic-assisted surgery and Stealth AXiS; CE Mark for Sphere-360; completed CathWorks and Anteris acquisitions.

## SEC filing metadata
- accession: 0001628280-26-008300
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000162828026008300/0001628280-26-008300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000162828026008300/mdt-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-008300
- JSON: https://secwatch.observer/filing/0001628280-26-008300.json
- Plain text: https://secwatch.observer/filing/0001628280-26-008300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.